Company news
Pharmacyte Biotech, Inc. (NASDAQ:PMCB) news
Pharmacyte Biotech, Inc. news releases on 6ix. Latest, Nov 25, 2025: PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position…
Press releases & updates
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
November 25, 2025
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 1, 2025
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
August 18, 2025
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
May 20, 2024
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
November 16, 2023
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
November 14, 2023
PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K
November 9, 2023
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
October 30, 2023
PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K
September 7, 2023
PharmaCyte Biotech Announces Final Results of Tender Offer
June 14, 2023
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
May 10, 2023
PHARMACYTE BIOTECH, INC. Management's Discussion and Analysis of Financial Conditions and Results of Operations (form 10-Q)
March 16, 2023
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
February 1, 2023
PHARMACYTE BIOTECH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
December 30, 2022
PHARMACYTE BIOTECH, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
November 18, 2022
PHARMACYTE BIOTECH, INC. : Change in Directors or Principal Officers (form 8-K)
November 7, 2022
PHARMACYTE BIOTECH, INC. : Change in Directors or Principal Officers, Shareholder Director Nominations, Other Events, Financial Statements and Exhibits (form 8-K)
October 14, 2022
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
October 6, 2022
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
August 14, 2022
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
July 27, 2022
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
July 20, 2022
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
July 18, 2022
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
July 10, 2022
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
July 4, 2022
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
June 14, 2022
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
June 12, 2022
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
June 7, 2022
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
June 1, 2022
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
May 22, 2022
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
April 26, 2022
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
April 18, 2022
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
April 12, 2022
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
April 4, 2022
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
March 21, 2022
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
March 15, 2022
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
February 21, 2022
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
February 13, 2022
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
January 5, 2022
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
January 3, 2022
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
December 27, 2021
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
December 14, 2021
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
December 7, 2021
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
November 29, 2021
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
November 11, 2021
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
September 26, 2021
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
September 20, 2021
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
September 15, 2021
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 7, 2021
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
August 30, 2021